LAM Pilot Study with Imatinib Mesylate (LAMP-1)
Technical Report,30 Sep 2014,29 Sep 2015
Medical University of South Carolina Charleston United States
Pagination or Media Count:
The LAMP-1 study is designed to generate short-term safety and efficacy data regarding imatinib mesylate imatinib in the treatment of Lymphangioleiomyomatosis LAM sufficient to power and design a phase 3 imatinib vs. placebo clinical trial. The hypothesis is that imatinib will be equivalent to rapamycin in short term efficacy and safety. Currently, most LAM patients are treated with rapamycin, which growth-inhibits but does not kill LAM cells. In the laboratory of Dr. DArmiento, imatinib was shown to completely block the growth of LAM cells through initiation of targeted cell death. This study employs a small clinical trial design using 20 participants at two institutions. 10 participants will be enrolled at Medical University of South Carolina and 10 at Columbia University. Importantly, VEGF-D level will be used to monitor LAM disease activity and therapeutic response.